You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
兆科眼科-B(06622.HK)公佈中期業績 上半年研發開支達1.234億元
格隆匯 08-18 17:33

格隆匯8月18日丨兆科眼科-B(06622.HK)發佈公吿,截至2021年6月30日止六個月,集團的研發開支達約人民幣1.234億元,較截至2020年6月30日止六個月的約人民幣3810萬元增加約223.9%。報吿期內,儘管2019冠狀病毒病爆發令集團進行中的臨牀試驗受到一定程度阻延(尤其是監於2021年5月廣東省南部出現爆發),惟集團盡力減輕2019冠狀病毒病的影響,並致力於中國及全球健康護理社區與集團的供應商及業務夥伴緊密合作,確保研發及製造繼續進行。集團透過不同途徑與供應商及全球業務夥伴維持密切聯繫,確保緊密合作不絕,彼此相互推動研發進程。

展望未來,集團秉承進取的增長策略,包括推進臨牀前至臨牀階段的不同資產,增強研發、臨牀、商業以至數碼基建等基礎能力。業務發展方面,集團計劃尋求與國內及國際醫藥公司合作的有利及創價機會。

集團三種仿製藥貝美前列素、貝美素噻嗎洛爾及依匹斯汀目前正待國家藥監局審理簡化新藥申請,預期將於2022年商業化。預期環孢素A眼凝膠將為集團首款商業化創新藥,最早可於2023年上市。此外,視乎與藥品審評中心持續溝通的結果,NTC010亦可能於2023年底前商業化。至於近期臨牀發展里程碑,集團預期於2021年第三季招募針對TAB014的第III期臨牀試驗的首名患者,並於2021年第四季取得NVK-002新藥試驗申請批准,進行第III期橋接研究。

拓展集團的銷售及營銷組織架構以及增強集團的商業能力為集團發展的關鍵中心領域。集團將繼續堅持創新銷售及營銷方針,以創新方式並最有效地鞏固與集團最重要的持份者的關係。因此,集團正於數碼技術方面大力進行投資,同時繼續主辦及參與不同眼科會議,從而提升集團的品牌知名度。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account